H

Hana Pharm Co Ltd
KRX:293480

Watchlist Manager
Hana Pharm Co Ltd
KRX:293480
Watchlist
Price: 11 130 KRW 1.92% Market Closed
Market Cap: 192.5B KRW
Have any thoughts about
Hana Pharm Co Ltd?
Write Note

Hana Pharm Co Ltd
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hana Pharm Co Ltd
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
H
Hana Pharm Co Ltd
KRX:293480
Additional Paid In Capital
â‚©104.5B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Yuhan Corp
KRX:000100
Additional Paid In Capital
-â‚©93.7B
CAGR 3-Years
-6%
CAGR 5-Years
-9%
CAGR 10-Years
-10%
SK Biopharmaceuticals Co Ltd
KRX:326030
Additional Paid In Capital
â‚©1.1T
CAGR 3-Years
0%
CAGR 5-Years
19%
CAGR 10-Years
N/A
Hanmi Pharm Co Ltd
KRX:128940
Additional Paid In Capital
â‚©368B
CAGR 3-Years
-1%
CAGR 5-Years
-1%
CAGR 10-Years
-1%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Additional Paid In Capital
â‚©99.8B
CAGR 3-Years
29%
CAGR 5-Years
43%
CAGR 10-Years
23%
C
Celltrion Pharm Inc
KOSDAQ:068760
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hana Pharm Co Ltd
Glance View

Market Cap
192.5B KRW
Industry
Pharmaceuticals

Hana Pharm Co., Ltd. engages in the research, development, and manufacture of pharmaceutical products. The company is headquartered in Hwaseong, Gyeonggi-Do and currently employs 657 full-time employees. The company went IPO on 2018-10-02. The company’s main products include cardiovascular drugs involves hypertension and hyperlipidemia medicines, as well as blood circulation improvement drugs; analgesics for severe pain and anesthetics for surgery and sedation; as well as gastrointestinal drugs such as peptic ulcer treatment and antispasmodics. The firm also provides antibiotics, dermatology analgesics, antipyretics and anti-inflammatory drugs.

Intrinsic Value
18 041.77 KRW
Undervaluation 38%
Intrinsic Value
Price
H

See Also

What is Hana Pharm Co Ltd's Additional Paid In Capital?
Additional Paid In Capital
104.5B KRW

Based on the financial report for Sep 30, 2024, Hana Pharm Co Ltd's Additional Paid In Capital amounts to 104.5B KRW.

What is Hana Pharm Co Ltd's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
0%

Over the last year, the Additional Paid In Capital growth was 0%.

Back to Top